These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 31058267

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD, Guo SJ, Chen SL, Liu ZF, Dong P, Zhang ZL, Jiang LJ, Yao K, Li YH, Han H, Qin ZK, Liu ZW, Zhou FJ.
    Zhonghua Wai Ke Za Zhi; 2017 Aug 01; 55(8):603-607. PubMed ID: 28789511
    [Abstract] [Full Text] [Related]

  • 3. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
    Steiner H, Leonhartsberger N, Stoehr B, Peschel R, Pichler R.
    Eur Urol; 2013 Jun 01; 63(6):1013-7. PubMed ID: 23021090
    [Abstract] [Full Text] [Related]

  • 4. Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group.
    Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Andreassen KE, Larsen SM, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A.
    Eur Urol Oncol; 2020 Jun 01; 3(3):382-389. PubMed ID: 31506250
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
    Speir RW, Calaway AC, Einhorn LH, Foster RS, Cary C.
    Urol Oncol; 2020 Aug 01; 38(8):687.e19-687.e23. PubMed ID: 32448503
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
    Djaladat H, Nichols C, Daneshmand S.
    Ann Surg Oncol; 2012 Jul 01; 19(7):2388-93. PubMed ID: 22395993
    [Abstract] [Full Text] [Related]

  • 8. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
    Labbate CV, Werntz RP, Galansky LB, Packiam VT, Eggener SE.
    Urol Oncol; 2020 Aug 01; 38(8):687.e13-687.e18. PubMed ID: 32305267
    [Abstract] [Full Text] [Related]

  • 9. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
    Nguyen CT, Stephenson AJ.
    Hematol Oncol Clin North Am; 2011 Jun 01; 25(3):593-604, ix. PubMed ID: 21570611
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW, Zhou FJ, Han H, Qin ZK, Yu SL, Li YH, Ye YL, Teng XY.
    Ai Zheng; 2008 Dec 01; 27(12):1302-6. PubMed ID: 19079998
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
    Heidenreich A, Pfister D, Witthuhn R, Thüer D, Albers P.
    Eur Urol; 2009 Jan 01; 55(1):217-24. PubMed ID: 18926622
    [Abstract] [Full Text] [Related]

  • 15. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
    Heidenreich A, Paffenholz P, Nestler T, Pfister D.
    Oncol Res Treat; 2018 Jan 01; 41(6):370-378. PubMed ID: 29772568
    [Abstract] [Full Text] [Related]

  • 16. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz JP.
    BJU Int; 2010 Sep 01; 106(6):779-85. PubMed ID: 20089110
    [Abstract] [Full Text] [Related]

  • 17. Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study.
    Bhambhvani HP, Greenberg DR, Kasman AM, DeRouen MC, Cheng I, Eisenberg ML, Shah SA.
    Urol Oncol; 2021 Mar 01; 39(3):197.e1-197.e8. PubMed ID: 33423934
    [Abstract] [Full Text] [Related]

  • 18. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.
    Considine S, Heaney R, Conroy R, Thornhill JA.
    Ir J Med Sci; 2016 Nov 01; 185(4):901-907. PubMed ID: 26692387
    [Abstract] [Full Text] [Related]

  • 19. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014.
    Tabakin AL, Shinder BM, Kim S, Rivera-Nunez Z, Polotti CF, Modi PK, Sterling JA, Farber NJ, Radadia KD, Parikh RR, Kim IY, Saraiya B, Mayer TM, Singer EA, Jang TL.
    Clin Genitourin Cancer; 2020 Apr 01; 18(2):e194-e201. PubMed ID: 31818649
    [Abstract] [Full Text] [Related]

  • 20. [Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND)].
    Nicolai N, Necchi A, Piva L, Stagni S, Catanzaro MA, Biasoni D, Milani A, Torelli T, Salvioni R.
    Urologia; 2010 Apr 01; 77(2):84-7. PubMed ID: 20890864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.